Chronic Myeloid Leukemia, Version 2.2024, NCCN Clinical Practice Guidelines in Oncology
2024 · Journal of the National Comprehensive Cancer Network · 96 citations
https://doi.org/10.6004/jnccn.2024.0007
B
B. Douglas Smith
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
308
Papers
11.3K
Citations
56
h-index
136
i10-index
B. Douglas Smith is an academic researcher from Johns Hopkins University. The author has contributed to research in topics: Acute Myeloid Leukemia Research & Chronic Myeloid Leukemia Treatments & Chronic Lymphocytic Leukemia Research. The author has an h-index of 56, co-authored 262 publications.
ORCID: 0000-0002-0903-7390Papers by this author
worksBosutinib for pretreated patients with chronic phase chronic myeloid leukemia: primary results of the phase 4 BYOND study
2020 · Leukemia · 82 citations
https://doi.org/10.1038/s41375-020-0915-9
Multi-Center Phase 2 Study of Pembroluzimab (Pembro) and Azacitidine (AZA) in Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML) and in Newly Diagnosed (≥65 Years) AML Patients
2019 · Blood · 69 citations
https://doi.org/10.1182/blood-2019-127345
Clinical benefit of glasdegib plus low-dose cytarabine in patients with de novo and secondary acute myeloid leukemia: long-term analysis of a phase II randomized trial
2021 · Annals of Hematology · 53 citations
https://doi.org/10.1007/s00277-021-04465-4
Impaired B cell immunity in acute myeloid leukemia patients after chemotherapy
2017 · Journal of Translational Medicine · 46 citations
https://doi.org/10.1186/s12967-017-1252-2
Final Clinical Results of a Phase II Study of High Dose Cytarabine Followed By Pembrolizumab in Relapsed/Refractory AML
2019 · Blood · 33 citations
https://doi.org/10.1182/blood-2019-126065
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat